However, of greater importanc e are inherited fac tors that affec t the kinetic s and dynamic s of numerous drugs. Genetic variation in genes for drug-metabolising enzymes, drug rec eptors, and drug transporters has been assoc iated with individual variability in the effic ac y and toxic ity of drugs. There is a relationship between genetic predisposition of an individual and his ability to metabolise a drug. Differenc es in drug metabolism c an lead to severe toxic ity or therapeutic failure due to a c hange in the ratio between the drug dose and the c onc entration of pharmac ologic ally ac tive substanc e in the blood, as the result of genetic modific ations. Genetic polymorphism based on the ability to metabolise the drug is assoc iated with three phenotype c lasses: -
• The phenotype of the extensive drug metabolizer ( EM) is c harac teristic of the normal population. EM alleles behave in a dominant way. Individuals with EM phenotype are either homozygous or heterozygous for the wild-type allele.
• The poor metabolizer phenotype ( PM) is assoc iated with the ac c umulation of spec ific drug substrates in the body, and is inherited as a rec essive autosomal trait due to mutation and/or deletion of both alleles responsible for phenotypic expression. Individuals with PM phenotype are either homozygotes or multiple heterozygotes for mutant alleles.
• The ultra-extensive metabolizer phenotype ( UEM) is c harac terized by enhanc ed drug metabolism due to gene amplific ation inherited as an autosomal dominant trait. Individuals with the ultrarapid phenotype are prone to therapeutic failure bec ause the drug c onc entrations in the plasma at normal doses are by far too low.
5 -2 0 % of patients c an belong to one of these risk groups, depending on the population studied.
Most of the works on this topic have c onc entrated on the c ytoc hrome P4 5 0 enzyme ( CYP) , whic h is a highly polymorphic enzyme that plays a key role in metabolising the majority of drugs in the human body.
T he cytochrome P450 superfamily
The superfamily of c ytoc hrome P4 5 0 ( CYP4 5 0 ) enzymes is the most important oxidative enzymatic system involved in drug metabolism. More than forty isoenzymes that show variable c atalytic ac tivity and uniform ac tion have been disc overed in human subjec ts to date. Although many of these enzymes exhibit genetic polymorphism, the molec ular basis of the modific ation has only been identified for some of them. The perc entage of individual isoenzymes in the human liver greatly varies ( Figure 1 ) . A majority of them belong to the group of family 3 A and 2 C isoenzymes, followed by family 1 A and 2 E isoenzymes. Of the 2 6 mammalian subfamilies, the CYP2 C, CYP2 D and CYP3 A subfamilies are involved in the metabolism of most c linic ally relevant drugs. It should be noted, however, that it is only relevant in c ase of drugs whic h are substrates exc lusively or mostly for this partic ular enzyme. Important substrates, induc ers and inhibitors of the major CYP enzymes are listed in Table 1 .
CYP2D6
The CYP2 D6 isoenzyme is by far most extensively c haracterized enzyme from the CYP4 5 0 superfamily whic h exhibits a polymorphic expression in humans. It ac c ounts for not more than 2 .6 % of CYP4 5 0 in the liver, and plays a very important role in the metabolism of almost 1 0 0 most c ommonly used drugs. The CYP2 D6 loc us has been identified as an array of at least three highly homologous genes, on the long arm of c hromosome 2 2 . In addition to the ac tive CYP2 D6 gene, c onsisting of nine exons and eight introns, an inac tive pseudogene, CYP2 D8 P, and an inac tive homologue, CYP2 D7 , are present in a tandem array.
Greater than 1 0 0 -fold variability in CYP2 D6 ac tivity has been observed within the general population and c an be attributed to genetic polymorphism of the CYP2 D6 gene, as the result of multiple mec hanisms inc luding single point mutations, insertions or deletions, and major rearrangements suc h as c omplete gene deletion, gene duplic ation or multiplic ation. Genetic polymorphism of the CYP2 D6 loc us, its func tional nuc leotide c hanges, and struc tural effec ts, and oc c urrenc e in study subjec ts are presented in Table 2 .
The major genetic polymorphisms assoc iated with the PM phenotype lead to the c omplete lac k of func tional protein.
• The most c ommon allele among PMs is CYP2 D6 * 4 . This allele results from a single-point mutation that alters messenger RNA ( mRNA) splic ing, resulting in failure to produc e an ac tive protein. The CYP2 D6 * 4 allele ac c ounts for more than 7 0 % of CYP2 D6 alleles in PM subjec ts.
• The sec ond most c ommon allele assoc iated with PM phenotype is the CYP2 D6 * 5 allele ( 2 5 %) , whic h represents c omplete deletion of CYP2 D6 .
• The third most c ommon allele among PMs is the CYP2 D6 * 3 allele ( 3 %) . CYP2 D6 * 3 results from deletion of a single nuc leotide within the c oding region, leading to a frameshift.
The earliest evidenc e of polymorphic expression was obtained during c linic al trials of the antihypertensive debrisoquin, sinc e when the ac tivity of debrisoquin hydroxylase ( CYP2 D6 ) has been taken as a standard for the phenotypic analysis of this polymorphism in c linic al trials.
As the CYP2 D6 polymorphisms are rec essive traits, the heterozygous individuals with one ac tive allele and one mutant allele have a metabolism, whic h does not overtly differ from a person with normal phenotype. However, these heterozygous individuals may have a slightly inc reased metabolic ratio that points to a defic ienc y of or reduc tion in the metabolic c apac ity. The individuals with these genotypes are referred to as EM and represent a great majority of the population. The ultraextensive ( UEM) phenotype results from duplic ation or amplific ation of CYP2 D6 * 2 allele on c hromosome 2 2 . The most frequent gene duplic ation results in two c opies of the CYP2 D6 * 2 gene on a single c hromosome ( CYP2 D6 * 2 x2 ) . However, even 1 2 -to 1 3 -fold amplific ation of the gene has been observed. The amplified gene produc t has func tionally the same but c atalytic ally inc reased ac tivity, whic h direc tly c orrelates with the amount of the same gene in the subjec ts with this allele. This unique allele has only been identified in the heterozygous form and results in exc essive expression of CYP2 D6 enzyme. This exc essive expression exerts a dramatic effec t on the metabolism and c learanc e of CYP2 D6 substrates, and results in sub-therapeutic drug c onc entrations at a standard dosage. Therefore, the individuals with UEM phenotype may require 'megadoses' of partic ular drugs ( espec ially those metabolised into inac tive metabolites) to ac hieve therapeutic effic ac y.
Signific ant ethnic variations have been rec orded in the prevalenc e of the CYP2 D6 PM phenotype. For instanc e, in Cauc asian populations of Europe and North Americ an, the prevalenc e of PM phenotype ranges between 5 % and 1 0 %. In the Croatian population, the prevalenc e of PM phenotype relative to the metabolising ability of 2 D6 isoenzyme in a small group of healthy volunteers was found to be 3 .7 %. The prevalenc e of PM phenotype is 1 .8 % in Blac k Americ ans, 1 .2 % in the Thai, 1 .0 % in the Chinese, 2 .1 % in the authentic Malayan population, and appears to be absent in the Japanese. In Cauc asians, the PM phenotype is a c onsequenc e of various mutant CYP2 D6 genotypes. Thus, 3 2 % of the Cauc asian population are heterozygous for the inac tivating mutant CYP2 D6 allele, so they may exhibit the intermediary phenotype whic h results from 2 D6 * 4 and 2 D6 * 3 alleles in almost 9 5 % of c ases. The prevalenc e of UEM phenotype in Cauc asians is 7 %, and results from CYP2 D6 * 2 allele in more than 9 5 % of c ases.
CYP2 D6 is a very polymorphic enzyme that c atalyses the metabolism of about 1 0 0 most c ommon drugs suc h as antiarrhythmic s, antidepressants, antipsyc hotic s, opioids, and so on. From the c linic al point of view, the c ommon therapeutic dose of antiarrhythmic s in these people will produc e a proarrhythmic effec t or some other toxic effec t.
Treatment with antidepressants will result in toxic ity in PM but will prove ineffic ient in UEM. In PM patients treated with antipsyc hotic s, tardive dyskinesia is observed. Also opioid drugs in PM may result in ineffic ac y of c odeine as analgesic , narc otic side effec ts, and eventually in dependenc y.
CYP2C19
The sec ond best c harac terized CYP polymorphism is the polymorphism of CYP2 C1 9 isoenzyme, whic h is involved in the metabolism of a number of drugs, inc luding c ertain barbiturates, diazepam, mephenytoin, omeprazole, proguanil and propanolol. Individuals c an be c harac terized as either extensive or poor metabolizers. The prevalenc e of PMs c harac terized by a reduc ed drug metabolising ability by CYP2 C1 9 enzyme, inherited as an autosomal rec essive trait, has been reported to be 2 %-5 % in Cauc asians, 4 %-8 % in Afric ans, 1 1 %-2 3 % in Orientals, and as high as 7 0 % in the residents of Vanuatu in Melanesia.
To date, more than 1 0 allelic variants of CYP2 C1 9 have been desc ribed ( Table 3 ) . CYP2 C1 9 * 2 and CYP2 C1 9 * 3 have been shown to be the main mutations c ontributing to PM phenotype. The main genetic impairment in PM phenotypes is the c onsequenc e of mutant CYP2 C1 9 * 2 allele, arising from single G® A mutation in exon 5 , resulting in the formation of a new, unnaturally splic ed CYP2 C1 9 mRNA. Translation of this mRNA transc ribes the formation of inac tive protein. This mutation is found in about 7 5 % -8 3 % of Cauc asians and Orientals genotyped as PMs. The other mutant allele, designated as CYP2 C1 9 * 3 , arises from G® A transition at position 6 3 6 in exon 4 of CYP2 C1 9 , whic h results in a premature stop c odon and produc es a trunc ated protein. This allele is rare in Cauc asians but appears to ac c ount for the remaining defec tive alleles in Oriental PMs. Clinic al implic ations of the CYP2 C1 9 polymorphism have not yet been thoroughly desc ribed. In the light of the relative perc entage of this isoenzyme and identific ation of an even greater number of pharmac eutic al substrates metabolised by CYP2 C1 9 , the c linic al relevanc e of this polymorphism will hopefully be eluc idated in the near future.
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CYP2C9
CYP2 C9 is a polymorphic enzyme of the CYP4 5 0 superfamily that c atalyses the metabolism of well-known drugs suc h as S-warfarin, tolbutamide, phenytoin, glipizide, losartan, and many non-steroidal anti-inflammatory drugs. The drug effec ts may inc lude hemorrhage, hypoglyc aemia, phenytoin toxic ity, and dec reased antihypertensive effec t in patients phenotyped as poor metabolizers. Bleeding is the major c omplic ation of warfarin therapy. At present, at least six different CYP2 C9 alleles have been found in Cauc asian population enc oding CYP2 C9 enzymes with potentially different c atalytic ac tivity ( Table 4 ) .
The most c ommon allele is designated as CYP2 C9 * 1 allele, and is c onsidered the wild type allele. CYP2 C9 * 2 allele has a point mutation ( C4 3 0 ® T) in exon 3 c ausing an Arg1 4 4 Cys amino ac id exc hange, whereas the point mutation ( A1 0 6 1 ® C) in exon 7 of CYP2 C9 * 3 results in Ile3 5 9 Leu exc hange. Rec ently, another substitutions at base pair 1 0 7 6 T® C, enc oding for an Ile3 5 9 Thr ( CYP2 C9 * 4 ) , and 1 0 8 0 C® G, enc oding for an Asp3 6 0 Glu amino ac id substitution ( CYP2 C9 * 5 ) have been identified. Finally, a new null polymorphism, CYP2 C9 * 6 , c ontaining an adenine base pair deletion at nuc leotide 8 1 8 has been identified, resulting in a premature stop c odon and a trunc ated, inac tive protein.
Numerous reports c onc erning CYP2 C9 * 2 and * 3 alleles suggest that the c atalytic ac tivity of the c orresponding enzyme is reduc ed c ompared with the wild type. Individuals possessing at least one variant allele exhibit signific ant reduc tions of 8 5 %-9 5 % in the CYP2 C9 metabolic ac tivity and c onsequently in dosing requirements of c ertain CYP2 C9 substrates. Cauc asians appear to c arry 8 %-2 0 % of CYP2 C9 * 2 , and 6 %-1 0 % of CYP2 C9 * 3 variants, whereas the respec tive figures in Asians range between 0 % and 2 -5 % only.
CYP2E1
The CYP2 E1 isoenzyme is responsible for the metabolism and bioac tivation of many pro-c arc inogens and some drugs, and is a major alternative system of metabolising ethanol. CYP2 E1 is enc oded by a gene loc ated on c hromosome 1 0 , with seven different loc i rec ognized to date. Two alleles of the gene have been identified, i.e. C and c 2 . The mutant c 2 allele lac king the RsaI restric tion site is assoc iated with a higher translation ac tivity, protein level, and enzyme ac tivity. The loc us polymorphism, related to modific ations of restric tion c leavage by Rsa I and Pst I endonuc leases, exhibits a 1 0 -fold inc rease in the gene transc ription ac tivity. The absenc e of the rare C allele has been assoc iated with lung c anc er in the Japanese, whereas no suc h assoc iation has been observed in Cauc asian and Afric an Americ ans in the USA.
The expression of CYP2 E1 mRNA is inc reased in the individuals who are homozygous or heterozygous for the c 2 mutant CYP2 E1 allele. Thus, this mutation may potentially lead to an inc reased func tional protein expression, and result in enhanc ed metabolism of CYP2 E1 substrates. Although there is evidenc e for the presenc e of the CYP2 E1 genetic polymorphism in humans, the exac t molec ular basis and its c linic al signific anc e have not yet been established.
CYP3A
The CYP3 A subfamily inc ludes 3 A4 and 3 A5 isoenzymes in adults, and 3 A7 isoenzyme in fetal liver. The predominating 3 A isoenzyme in the liver of adults is 3 A4 , whic h ac c ounts for 2 0 %-4 0 % of total hepatic P4 5 0 c ytoc hrome. It is also widely expressed throughout the gastrointestinal 
T he drug-metabolizing enzymes in cardiovascular pharmacology
Some of the drugs used in c ardiovasc ular pharmac ology and metabolised by polymorphic CYP4 5 0 enzymes are presented in Table 5 .
Antiarrhythmics
( RS) -propafenone is a widely used c lass 1 C antiarrhythmic drug, whic h is hydroxylated by CYP2 D6 to 5 -hydroxypropafenone. The drug is both a ß -bloc ker and sodium c hannel bloc ker. The ß -bloc king ac tivity of ( RS) -propafenone is mostly due to S-enantiomer, whereas the sodium c hannel bloc king ac tivity is due to both R and S enantiomers. The metabolic produc t, 5 -hydroxypropafenone, has different pharmac ologic ac tivity from propafenone, and is mainly a sodium c hannel bloc ker with minor ß -adrenergic antagonist effec t. Genotyping has shown that poor metabolizers have more ß -bloc kade and severe side effec ts when c ompared with extensive metabolizers. Consequently, another drug that is as effec tive and less toxic might be c onsidered for these patients.
Flec ainide is another c lass 1 C antiarrhythmic drug, whic h is also metabolised by CYP2 D6 but its metabolic produc ts are inac tive. The dose rec ommendations are only valid for the dose range, taking into ac c ount individual differenc es in the metabolising ac tivity due to genetic polymorphism.
Beta blockers
Carvedilol, a ß -bloc ker with a-adrenergic -bloc king effec ts, metabolised by CYP2 D6 and CYP2 C9 , is a rac emic drug whose a1 bloc king ac tivity is mainly supported by the ( S) -enantiomer, while the ß 1 -bloc king ac tivity is a property of the two enantiomers. The ( R) -enantiomer is better metabolised by CYP2 D6 , whic h explains the differenc es in a1 /ß 1 relative ac tivities, depending on the genotype and expressed alleles.
Metoprolol is another ß -bloc ker with ß -adrenergicbloc king effec t, and is also metabolised by CYP2 D6 . Thus the treatment has to be adjusted ac c ording to the patient's responsiveness.
Anticoagulants
Warfarin is an oral antic oagulant mostly used in patients with venous and arterial thromboembolism. To keep the WHO International Normalised Ratio ( INR) values between 2 .0 and 3 .0 , the doses of warfarin fluc tuate from 1 mg to 2 0 or more mg daily. Standardized induc tion sc hemes with monitoring of INR over the first 4 days have shown a modest 6 9 % suc c ess rate. Suc h inter-individual variations are partly due to the presenc e of polymorphisms of the CYP2 C9 gene. Warfarin is a rac emic drug with a 3 -to 5 -times higher antic oagulant effec t of ( S) -enantiomer than of the ( R) form. CYP2 C9 , a CYP4 5 0 enzyme responsible for the metabolism of S-warfarin, c onverts S-warfarin into inac tive 6 -hydroxy and 7 -hydroxy metabolites. The CYP2 C9 * 2 variant is about 1 2 % and CYP2 C9 * 3 is less than 5 % as effic ient as the wild type enzyme. Up to 2 0 % of the general population c ould be c arriers of the mutant allelic forms and behave as poor metabolizers. Detail genotyping have shown strong c orrelation between the need of a low dose of warfarin and the presenc e of at least one mutant allele of CYP2 C9 gene. These subjec ts have diffic ulties at the time of induc tion of antic oagulation as indic ated by longer hospitalisation or longer visiting outpatient c linic s. The dec reased metabolism of warfarin also makes c arriers four times more susc eptible to bleeding c omplic ations in spite of low dose administration. The c onc ern for this c omplic ation is justified by the high mortality risk, whic h is inc reased in the elderly population. Therefore, identific ation of these polymorphisms before starting therapy should help prevent c omplic ations. 
Drug
T oxic-metabolizing enzyme and risk factors
An interesting applic ation of researc h on genetic polymorphisms refers to the toxic -metabolising enzymes, whic h detoxify alc ohol and tobac c o produc ts, two wellidentified risk fac tors in c ardiology.
Alcohol
Moderate alc ohol c onsumption is c onsistently assoc iated with reduc ed risk of myoc ardial infarc tion ( the so-c alled 'Frenc h paradox') , nevertheless, it is not c lear whether the apparent benefit of alc ohol is due to c onstituents of the alc oholic beverages other than ethanol or in fac t reflec ts the lifestyle fac tor. Alc ohol dehydrogenase ( ADH) izoenzymes are also drug metabolizing enzymes that oxidize ethanol and play a major detoxific ation role upon alc ohol c onsumption. Although several ADH izogenes exist ( ADH1 , 2 , 3 ) , ADH2 and ADH3 are the only loc uses that give different alleles with different kinetic properties ( Table 6 ) . Its pharmac okinetic s shows that the ?1 ?1 homodimer is assoc iated with a fast rate of oxidation as c ompared to ?2 ?2 . Homozygosity for ?2 ?2 is assoc iated with the highest level of plasma HDL and reduc ed risk of myoc ardial infarc tion as c ompared to homozygosity for ?1 ?1 .
T obacco
Glutathione S transferase ( GST) belongs to the drugmetabolizing enzymes that detoxify or ac tivate several drugs as well as c hemic als in c igarette smoke. GST c an eliminate the produc ts of oxidative stress and also c arc inogenic c ompounds. The gene exists in two main forms, GST M1 and GST T1 , with different c apac ity to detoxify tobac c o c ompounds. Some c ase c ohort studies in c oronary patients have indic ated that ever-smokers with GST M1 -0 were at a nearly 2 -fold c oronary risk c ompared with that found in ever-smokers with GST M1 -1 or never-smokers with GST M1 -0 .
Lipid lowering drugs
Lipid lowering drugs suc h as statins are widely used to reduc e c holesterol and triglyc eride levels, as they may prevent the development of isc hemic events in patients with dyslipidaemia or c ardiovasc ular disease. All statins lower c holesterol level through reversible and c ompetitive inhibition of HMG-CoA reduc tase, an enzyme involved in the biosynthesis of c holesterol and other sterols. This mec hanism leads to LDL c holesterol reduc tion, triglyc eride reduc tion, and HDL c holesterol elevation. The synthetic statins atorvastatin, c erivastatin and fluvastatin appear to be as effic ac ious as the natural ones suc h as lovastatin, pravastatin, and simvastatin. Pharmac okinetic properties of statins, listed in Table 7 , may suffic e to affec t the c hoic e of one statins over another in a given c linic al situation.
Exc ept for pravastatin, all statins are subjec t to extensive first-pass metabolism by the CYP4 5 0 enzyme. Atorvastatin, lovastatin and simvastatin are metabolised by CYP3 A4 , whereas fluvastatin is metabolised by CYP2 C9 . Cerivastatin is jointly metabolised by CYP3 A4 and CYP2 C8 . Pravastatin does not undergo CYP4 5 0 metabolism. Statins metabolised by a c ommon enzymatic system may differ in the extent of metabolism by this system, so that eac h statin has a different potential for drug ac tions mediated through mutation in CYP4 5 0 genes. A study c onduc ted in healthy volunteers to measure the c atalytic ac tivity of CYP2 D6 polymorphism has revealed that hepatic metabolism of simvastatin is inhibited by the presenc e of the variant allele of the CYP2 D6 polymorphism. In homozygous c arriers, poor metabolizers ( who represent 3 % to 1 0 % of the Cauc asian population) , a given dose of simvastatin has a higher c holesterol-lowering effec t c ompared with the wild type c arriers. In c ontrast, c arriers of the duplic ated or multiplic ated wild type CYP2 D6 gene, c alled ultrarapid metabolizers, need higher doses of simvastatin to reduc e c holesterol levels to the same extent. Knowing in advanc e the genetic c harac teristic s of the patients might help establish the right doses to be presc ribed.
Future promises
Genetic heterogeneity appears to be a signific ant sourc e of variability observed in the response to drugs. The proc ess to enhanc e the effic ac y of administered drugs is very old. A hundred years ago, the c linic ians presc ribed the drug only on the basis of physic al examination. At the end of the 2 0 th c entury, therapeutic dec ision was greatly fac ilitated by laboratory support and the proc ess of therapeutic drug monitoring. Now, we have entered a new era with pharmac ogenetic s and pharmac ogenomic s, whic h appear highly promising in enhanc ing the support to therapeutic dec ision-making, predic ting patients who are most likely to respond best to a partic ular drug or in whom the drug will yield optimal effec ts. An individual's polymorphism and possible response to a partic ular drug c an be assessed by a dual approac h, i.e. by phenotyping or genotyping.
Phenotyping/genotyping
Phenotyping inc ludes administration of the respec tive drug ( its metabolism being known to exc lusively depend on a spec ific enzyme func tion) , followed by determination of the metabolic ratio ( MR) , defined as a ratio of drug dose or unc hanged drug and its metabolites measured in serum or urine. Determination of the phenotype relative to the referenc e substrate allows for predic tion of phenotype for other substrates. Genotyping inc ludes identific ation of spec ific gene mutations that result in a spec ific phenotype. These mutations inc lude gene mutations that lead to overexpression ( gene duplic ation) , absenc e of ac tive protein produc t ( null allele) , or formation of a mutant protein with a dec reased c atalytic ac tivity ( inac tivating allele) .
In pharmac okinetic studies, preferenc e is given to phenotyping over genotyping for detec ting drug-drug interac tions or impairments in the overall proc ess of drug metabolism. However, the phenotyping approac h also suffers from a number of serious drawbac ks, e.g., c omplex testing protoc ols, risk of undesired drug reac tions, problems of erroneous phenotype alloc ation due to c oadministration of several drugs or possible c onfounding disease effec ts. The methods of genotyping, on the other hand, require small amounts of blood or tissue, they are not influenc ed by either underlying disease or c urrently used drugs, and results are available within 4 8 -7 2 hours, thus allowing for prompt intervention.
Methods of genotyping
A number of molec ular bioc hemistry methods used for rec ognition of genetic mutations are c urrently available ( Table 8 ) . Almost all of these methods are based on the tec hnique of the respec tive DNA fragment amplific ation, for whic h Mullis was awarded Nobel Prize in 1 9 9 3 . Chain reac tion of DNA synthesis by DNA polymerase or simply polymerase c hain reac tion ( PCR) is a relatively new method of nuc leic ac id synthesis in vitro, by use of whic h a spec ific DNA fragment c an be multiplied in a large number of c opies. DNA is isolated from EDTA blood, and Table 8 . Methods of a spec ific region of the gene under study is being amplified by oligonuc leotide DNA fragments ( primers) c omplementary with the borderline segments of the known DNA to be amplified ( target DNA) .
The produc t of PCR amplific ation is then submitted to subsequent reac tions to identify a known or unknown mutation and/or deletion ( RFLP, SSCP, multiplex PCR, allele-spec ific PCR, etc .) ( Figure 2 ) .
PCR-RFLP
The method of restric tion fragment length polymorphism ( RFLP) is based on spec ific PCR produc t c leavage by restric tion endonuc leases c apable of c leavage of doublestranded DNA with a high level of spec ific ity for nuc leotide sequenc es. The size of digestion produc ts is assessed by agarose gel elec trophoresis, staining with ethidium bromide, and UV transillumination. Differenc es in the size of DNA fragments produc ed as the result of digestion with restric tion endonuc leases are known as the restric tion fragment length polymorphism. Comparison of the PCR produc t restric tion fragment size between a c ontrol and study subjec t allows for rec ognition of the subjec t's genetic mutation and determination of the subjec t's genotype and phenotype.
PCR-SSCP
Upon genomic DNA amplific ation, the PCR produc t is being denatured, yielding single strand DNA fragments. These single strand fragments ac quire varying c onformation in spac e, depending on their primary nuc leotide sequenc e. A single nuc leotide differenc e is quite enough for two denatured single strand molec ules ( ssDNA) to ac quire different spatial c onformations. Due to these variabilities, c harac teristic distributions of single strand bands c an be disc riminated in a high resolution gel, depending on the primary DNA sequenc e and, ac c ordingly, on the respec tive genotype. Bec ause of its simple performanc e, SSCP is mostly employed on sc reening for known as well as new mutations.
Multiplex allele specific PCR amplification
Multiplex PCR is a method whic h allows for simultaneous detec tion of all known polymorphic genes that result in a PM or EM phenotype. First, another DNA fragment inc luding c omplete CYP2 D6 gene is enzymatic ally amplified by PCR from genomic DNA. Then, two PCR reac tions follow from this DNA fragment: one with primers spec ific for the wild type, and the other with primers spec ific for the mutant type. The c onc lusion on the subjec t's homo-/heterozygosity is derived from these two reac tions. Upon PCR produc t elec trophoresis, the genotype of eac h sample c an be direc tly read ac c ording to the oc c urrenc e or absenc e of partic ular DNA bands in the gel. For a very large number of samples, some of the options available c an be c hosen, e.g., oligonuc leotide ligation assay ( OLA) , TaqMan allelic disc rimination assay ( TaqMan) , mic rosequenc ing, and c hip or mic roarrays tec hniques, whic h enable simultaneous genotyping of hundreds to tens of thousands of samples. These highly effic ient tec hniques are mostly used for genotyping of known polymorphisms. Apart from SSCP and mic rosequenc ing, for identific ation of new, as yet unknown polymorphisms, other methods are also used, e.g., denaturing gradient gel elec trophoresis ( DGGE) , heteroduplex analysis ( HA) , PCR direc t sequenc ing ( PCR-DS) , and c hemic al mismatc h c leavage ( CMC) .
The usability of the methods presently available in molec ular diagnosis depends on many c riteria, ac c ording to whic h eac h of the methods has c ertain advantages as well as shortc omings ( Table 9 ) . It is therefore of paramount importanc e to find proper balanc e in order to obtain an optimal response at the lowest level of limitations. The method of SSCP is most c ommonly employed for c linic al purpose at molec ular bioc hemistry laboratories for detec tion of partic ular polymorphisms, bec ause of its simple performanc e, rapidity and c ost effec tiveness, whereas the multiplex allele spec ific PCR is preferred for simultaneous detec tion of a number of mutations.
Clinical use of pharmacogenetics
There is strong evidenc e for a signific ant role of the genetic polymorphism of the enzymes involved in the metabolism of drugs in the oc c urrenc e of adverse effec ts. Determination of these genetic variations is highly c linic ally relevant for predic ting the unwanted or inadequate response to a partic ular drug as well as for predic ting an inc reased risk. There are two approac hes as to when the pharmac ogenetic testing should be done.
Ac c ording to one approac h, the pharmac ogenetic testing should only be performed when a patient shows signs of toxic ity upon therapy administration or fails to respond appropriately to the therapy presc ribed. Ac c ording to the other approac h, health c are institutions should selec t drugs that require pharmac ogenetic testing before therapy introduc tion. The dec ision is thereby based on the assessment of the polymorphic enzyme signific anc e in the metabolism of the respec tive drug intended to be used in the treatment. If the drug is metabolised by a polymorphic enzyme, this being the only route of its inac tivation, it c an be presumed to have a major impac t on the metabolism, pharmac okinetic s and pharmac odynamic s of the drug, and thus on its effic ac y.
It seems ac c eptable that genotyping c ould be indic ated in any c ase when the drug of c hoic e is a substrate for a polymorphic enzyme, or in individuals exhibiting a suboptimal response to drugs that are substrates for polymorphic enzymes. The advantage of genotyping lies in the fac t that it allows for the PM or UEM phenotype properties of an individual to predic t, and these data c an primarily prove useful for dose adjustment or c hoic e of an alternative drug that is not the polymorphic enzyme substrate. Although the pre-dosing sc reening of patients would be assoc iated with some additional c ost, it would c ertainly be c ounterbalanc ed by reduc tion of the c ost of treatment for toxic episodes, therapeutic failures, or subsequent interventions due to therapeutic errors
Conclusions
The advantage of pharmac ogenetic testing in individual patients lies in the fac t that the results provide an ac c urate and c onstant information on the patient's drug metabolizing ability before therapy introduc tion, thus allowing for proper dose c hoic e and optimisation. The potential of pharmac ogenomic s in differentiating responders from non-responders in a patient population with the same diagnosis is promising for its high prac tic al implic ations, espec ially for drugs that are substrates of highly polymorphic enzymes ( Figure 3 ) . The task of c linic al laboratories is to adopt this new laboratory diagnostic tool that allows for detec tion of allele mutations and rec ognition of homozygous and heterozygous c arriers of mutant genes.
